ITIH5 downregulation in breast cancer, caused by promoter hypermethylation, is associated with poorer clinical outcome, and reduced protein expression was proved to be a bad prognostic marker in invasive node-negative patients (Veeck et al, 2008). Here, ITIH5 is linked to breast cancer.